Time trends of selected mutations with prevalence greater than 0.3%. Data are no (%) of samples with mutation unless stated otherwise

Mutation	Year (no of samples)
	2002 (n=547)	2003 (n=766)	2004 (n=1364)	2005 (n=2054)	2006 (n=2455)	2007 (n=2525)	2008 (n=2651)	2009 (n=2221)
Protease inhibitors
M46I/L	12 (2.19)	9 (1.17)	13 (0.95)	17 (0.83)	14 (0.57)	14 (0.55)	15 (0.57)	13 (0.59)
V82A/T/F/S/C/M	9 (1.65)	10 (1.31)	19 (1.39)	12 (0.58)	7 (0.29)	8 (0.32)	3 (0.11)	7 (0.32)
L90M	8 (1.46)	9 (1.17)	20 (1.47)	24 (1.17)	18 (0.73)	12 (0.48)	16 (0.60)	21 (0.95)
Non-nucleoside reverse transcriptase inhibitors
K103N/S	21 (3.84)	28 (3.66)	40 (2.93)	57 (2.78)	67 (2.73)	76 (3.01)	89 (3.36)	62 (2.79)
Y181C/I/V	5 (0.91)	9 (1.17)	10 (0.73)	17 (0.83)	11 (0.45)	13 (0.51)	12 (0.45)	9 (0.41)
G190A/S/E	7 (1.28)	7 (0.91)	10 (0.73)	14 (0.68)	9 (0.37)	8 (0.32)	8 (0.3)	3 (0.14)
Nucleos(t)ide reverse transcriptase inhibitors
M41L	27 (4.94)	17 (2.22)	46 (3.37)	49 (2.39)	49 (2.00)	41 (1.62)	51 (1.92)	33 (1.49)
K65R	1 (0.18)	3 (0.39)	3 (0.22)	1 (0.05)	1 (0.04)	3 (0.12)	3 (0.11)	0
D67N/G/E	12 (2.19)	9 (1.17)	20 (1.47)	21 (1.02)	21 (0.86)	13 (0.51)	13 (0.49)	9 (0.41)
K70E*	6 (1.10)	9 (1.17)	4 (0.29)	5 (0.24)	6 (0.24)	2 (0.08)	4 (0.15)	3 (0.14)
L74I/V*	5 (0.91)	3 (0.39)	3 (0.22)	5 (0.24)	4 (0.16)	3 (0.12)	2 (0.08)	1 (0.05)
Y115F*	0	2 (0.26)	1 (0.07)	1 (0.05)	1 (0.04)	0	1 (0.04)	2 (0.09)
M184I/V	11 (2.01)	13 (1.70)	15 (1.1)	15 (0.73)	13 (0.53)	14 (0.55)	9 (0.34)	7 (0.32)
L210W	12 (2.19)	7 (0.91)	15 (1.1)	13 (0.63)	12 (0.49)	9 (0.36)	12 (0.45)	8 (0.36)
T215Y/F	12 (2.19)	9 (1.17)	9 (0.66)	17 (0.83)	7 (0.29)	3 (0.12)	2 (0.08)	2 (0.09)
T215I/S/C/D/V/E	35 (6.40)	35 (4.57)	59 (4.33)	82 (3.99)	86 (3.50)	82 (3.25)	102 (3.85)	87 (3.92)
K219Q/E/N/R	10 (1.83)	19 (2.48)	31 (2.27)	34 (1.66)	34 (1.38)	33 (1.31)	41 (1.55)	39 (1.76)

*Included because these are major mutations to recommended first line antiretroviral drugs.